肿瘤细胞治疗研究
英文原题：DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review.
神经内分泌肿瘤（NENs）因其异质性和有限的治疗选择，在诊断和治疗上构成挑战。
神经内分泌肿瘤（NENs）因其异质性和有限的治疗选择，在诊断和治疗方面仍是一项挑战。由于这类肿瘤随时间推移倾向于去分化，常规影像学技术和治疗策略在随访过程中可能变得不可靠。因此，NEN患者的管理需要新的诊断和治疗选择。Delta样配体3（DLL3）作为Notch受体的抑制性配体，已成为NENs新型诊断和治疗策略的潜在靶点，因为DLL3的过表达与多种NENs的肿瘤进展、不良预后和去分化相关。本叙述性综述审视了关于DLL3的当前证据，包括其结构、功能以及与NENs肿瘤发生的关联。综述了正在进行的探索DLL3作为新兴诊断标志物作用的研究。同时也讨论了有前景的治疗选择，如抗体偶联药物、CAR-T细胞和放射免疫偶联物。
Neuroendocrine neoplasms (NENs) represent a diagnostic and therapeutic challenge, due to their heterogeneity and limited treatment options. Conventional imaging techniques and therapeutic strategies may become unreliable during follow-up, due to the tendency of these neoplasms to dedifferentiate over time. Therefore, novel diagnostic and therapeutic options are required for the management of NEN patients. Delta-like ligand 3 (DLL3), an inhibitory ligand of Notch receptor, has emerged as a potential target for novel diagnostic and therapeutic strategies in NENs, since overexpression of DLL3 has been associated with tumor progression, poor prognosis and dedifferentiation in several NENs. This narrative review examines the current evidence about DLL3, its structure, function and association with tumorigenesis in NENs. Ongoing studies exploring the role of DLL3 as an emerging diagnostic marker are reviewed. Promising therapeutic options, such as antibody-conjugated drugs, CAR-T cells and radioimmunoconjugates, are also discussed.
MEMBER ACCOUNT
登录成功会直接打开下一页。
